MCID: CYT008
MIFTS: 56

Cytomegalovirus Infection

Categories: Blood diseases, Immune diseases

Aliases & Classifications for Cytomegalovirus Infection

MalaCards integrated aliases for Cytomegalovirus Infection:

Name: Cytomegalovirus Infection 53 3 17
Cytomegalovirus Infections 42 71

Classifications:



External Ids:

UMLS 71 C0010823

Summaries for Cytomegalovirus Infection

NINDS : 53 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.

MalaCards based summary : Cytomegalovirus Infection, also known as cytomegalovirus infections, is related to congenital cytomegalovirus and colitis, and has symptoms including fever and pruritus. An important gene associated with Cytomegalovirus Infection is RAG1 (Recombination Activating 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Triamcinolone and Ganciclovir have been mentioned in the context of this disorder. Affiliated tissues include kidney, liver and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

MedlinePlus : 42 Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50 percent and 80 percent of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

CDC : 3 Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. When a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. About one out of every 200 babies is born with congenital CMV infection. About one in five babies with congenital CMV infection will have long-term health problems.

Related Diseases for Cytomegalovirus Infection

Diseases related to Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1120)
# Related Disease Score Top Affiliating Genes
1 congenital cytomegalovirus 34.1 TNF IL1B CCL2
2 colitis 31.4 TNF IL6 IL1B CXCL8
3 cytomegalovirus retinitis 31.3 TNF HLA-B HLA-A
4 ulcerative colitis 31.3 TNF IL6 IL1B CXCL8
5 exanthem 31.2 TNF MTOR IL6 CXCL8
6 vasculitis 31.1 TNF IL6 HLA-B CCL2
7 chlamydia pneumonia 31.1 TNF IL6 CXCL8
8 rubella 31.1 TNF IL6 HLA-B HLA-A
9 cerebral palsy 31.0 TNF IL6 IL1B CXCL8
10 bronchiolitis obliterans 31.0 TNF IL6 CXCL8
11 diarrhea 31.0 TNF IL6 IL1B CXCL8
12 toxoplasmosis 30.9 TNF IL6 IL1B CCL3
13 myelitis 30.9 TNF IL6 CXCL8
14 graft-versus-host disease 30.9 TNF IL6 IL1B HLA-B HLA-A FAS
15 meningoencephalitis 30.9 TNF IL6 CCL5 B2M
16 iridocyclitis 30.8 TNF IL6 HLA-B
17 acquired immunodeficiency syndrome 30.8 TNF IL6 IL1B HLA-B CCL3 B2M
18 gastroenteritis 30.8 TNF IL6 IL1B CXCL8
19 perinatal necrotizing enterocolitis 30.8 TNF IL6 IL1B CXCL8
20 gastritis 30.8 TNF IL6 IL1B CXCL8 CCL5
21 polyradiculopathy 30.8 TNF IL6 IL1B
22 esophagitis 30.8 TNF IL6 IL1B CXCL8 CCL5
23 crohn's disease 30.8 TNF IL6 IL1B CXCL8 CCL2
24 chlamydia 30.8 TNF IL6 IL1B CXCL8 CCL2
25 cystitis 30.7 TNF IL6 CXCL8 CCL2
26 bacterial sepsis 30.7 TNF IL6 CXCL8
27 herpes simplex 30.7 TNF IRF3 HLA-B CCL5
28 crohn's colitis 30.7 TNF IL1B CXCL8
29 toxic shock syndrome 30.7 TNF IL6 IL1B CXCL8
30 pharyngitis 30.7 TNF IL6 IL1B CXCL8
31 pericarditis 30.6 TNF IL6 IL1B CXCL8
32 transverse myelitis 30.6 TNF IL6 CXCL8
33 cholangitis 30.6 TNF IL6 HLA-B CXCL8
34 autoimmune myocarditis 30.6 TNF CCL2
35 lymphocytic choriomeningitis 30.6 IRF3 IL6 CXCL8
36 neonatal jaundice 30.6 TNF IL6 IL1B
37 respiratory failure 30.6 TNF IL6 IL1B CXCL8 CCL5
38 atherosclerosis susceptibility 30.6 TNF IL6 IL1B CXCL8 CCL2
39 acute pancreatitis 30.5 TNF IL6 IL1B CXCL8
40 ileitis 30.5 TNF IL6 CCL5
41 duodenal ulcer 30.5 TNF IL6 IL1B CXCL8
42 herpes zoster 30.5 TNF HLA-B HLA-A
43 thrombocytopenia 30.5 TNF IL6 IL1B FAS CXCL8 CCL2
44 erythema multiforme 30.5 TNF IL6 FAS CXCL8 CCL5
45 ileus 30.5 TNF IL6 IL1B CCL2
46 optic neuritis 30.5 TNF IL1B CXCL8
47 gastric ulcer 30.5 TNF IL6 IL1B CXCL8
48 newborn respiratory distress syndrome 30.4 IL6 IL1B CXCL8
49 vaccinia 30.4 TNF IRF3 IL6 HLA-A
50 post-transplant lymphoproliferative disease 30.4 TNF IL6 B2M

Comorbidity relations with Cytomegalovirus Infection via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Cytomegalovirus Infection:



Diseases related to Cytomegalovirus Infection

Symptoms & Phenotypes for Cytomegalovirus Infection

UMLS symptoms related to Cytomegalovirus Infection:


fever, pruritus

GenomeRNAi Phenotypes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 10.38 HLA-A HLA-B HLA-G
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.38 HLA-A HLA-B HLA-G
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.38 HLA-E
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.38 HLA-A HLA-B HLA-G
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.38 HLA-E
6 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.38 HLA-E
7 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.38 HLA-A HLA-B HLA-G
8 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.38 HLA-E
9 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.38 HLA-A HLA-B HLA-G
10 Increased shRNA abundance (Z-score > 2) GR00366-A-31 10.38 HLA-A HLA-B HLA-G HLA-E
11 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.38 HLA-A HLA-B HLA-G
12 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.38 HLA-A HLA-B HLA-G
13 Decreased viability with paclitaxel GR00179-A-1 9.9 MTOR SP1 CASP3
14 Decreased viability with paclitaxel GR00179-A-2 9.9 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.9 MTOR SP1
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 CASP3 CXCL8 FAS IL1B NFKB1 SP1
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 CASP3 CXCL8 FAS IL1B NFKB1 SP1

MGI Mouse Phenotypes related to Cytomegalovirus Infection:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 B2M CASP3 CCL5 FAS HLA-G IL1B
2 homeostasis/metabolism MP:0005376 10.13 B2M CASP3 CREB1 FAS HLA-G IL1B
3 cardiovascular system MP:0005385 10.1 B2M CASP3 CREB1 FAS IL1B IL6
4 immune system MP:0005387 10.07 B2M CASP3 CCL2 CCL5 FAS HLA-G
5 integument MP:0010771 9.81 B2M CASP3 FAS IL1B IL6 NFKB1
6 respiratory system MP:0005388 9.65 CASP3 CREB1 FAS IL6 IRF3 MTOR
7 skeleton MP:0005390 9.32 CASP3 CREB1 FAS IL1B IL6 MTOR

Drugs & Therapeutics for Cytomegalovirus Infection

Drugs for Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
4
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
9
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
10
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
11
Pancrelipase Approved, Investigational Phase 4 53608-75-6
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Mycophenolic acid Approved Phase 4 24280-93-1 446541
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
16
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
17
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
18
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
19
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
20
Dolutegravir Approved Phase 4 1051375-16-6 54726191
21
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
22
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
23 Immunologic Factors Phase 4
24 Immunoglobulins Phase 4
25 Antibodies Phase 4
26 triamcinolone acetonide Phase 4
27 Triamcinolone diacetate Phase 4
28 Triamcinolone hexacetonide Phase 4
29 Ganciclovir triphosphate Phase 4
30 Antifungal Agents Phase 4
31 Vaccines Phase 4
32 Liver Extracts Phase 4
33 Dermatologic Agents Phase 4
34 Hydrocortisone hemisuccinate Phase 4
35 Hydrocortisone 17-butyrate 21-propionate Phase 4
36 dipyrone Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Central Nervous System Depressants Phase 4
39 Tocolytic Agents Phase 4
40 Anesthetics Phase 4
41 Calcium, Dietary Phase 4
42 calcium channel blockers Phase 4
43 Anticonvulsants Phase 4
44 pancreatin Phase 4
45 Hormone Antagonists Phase 4
46 Antineoplastic Agents, Hormonal Phase 4
47 glucocorticoids Phase 4
48 Hormones Phase 4
49 Antimetabolites Phase 4
50 Chlorpheniramine, phenylpropanolamine drug combination Phase 4

Interventional clinical trials:

(show top 50) (show all 296)
# Name Status NCT ID Phase Drugs
1 An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients. Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Unknown status NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
3 The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
4 Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients. Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
5 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients Completed NCT01552369 Phase 4 Valganciclovir
6 Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
7 Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
8 A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
9 A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®). Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
10 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
11 A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
12 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
13 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
14 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
15 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
16 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
17 Tacrolimus In Combination, Tacrolimus Alone Compared (TICTAC Trial): A Prospective Randomized Trial Of Minimized Immunosuppression In Adult Heart Transplant Recipients Completed NCT00299221 Phase 4 Tacrolimus;combination therapy
18 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
19 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
20 Prospective Comparative Study of the Humoral and Cell-Mediated Immune Responses to the Trivalent Subviron Influenza Vaccine in Pediatric Liver Transplant Recipients as an Indicator for Response of Immunocompromised Subjects to Vaccination Against Agents of Bioterrorism Completed NCT00133510 Phase 4
21 In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial Completed NCT01651585 Phase 4 Valacyclovir arrow
22 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
23 Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients Completed NCT00034385 Phase 4 Valganciclovir
24 A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT) Completed NCT02550639 Phase 4
25 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus) Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
26 Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
27 Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone Recruiting NCT03468478 Phase 4 Sirolimus;Everolimus;Mycophenolic acid
28 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
29 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
30 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
31 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
32 The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group Unknown status NCT02005822 Phase 3 Valganciclovir
33 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
34 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
35 Participation of Cytomegalovirus Infection or an Autoimmune Process in T Lymphocyte Activation of HIV-1 Infected Patients With Undetectable Viral Load on Antiretroviral Therapy. Completed NCT04067869 Phase 3
36 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Completed NCT02351102 Phase 2, Phase 3 Valacyclovir;Placebo
37 Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
38 A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir
39 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
40 A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112) Completed NCT00466817 Phase 3 Valganciclovir
41 A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant Completed NCT01077908 Phase 3 Best available antiviral drug therapy
42 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients Completed NCT00294515 Phase 3 Valganciclovir;Valganciclovir
43 A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration Completed NCT00372229 Phase 3 Pre-emptive therapy;valganciclovir [Valcyte]
44 A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes) Completed NCT00001038 Phase 3 Valacyclovir hydrochloride;Acyclovir
45 A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants Completed NCT00497796 Phase 3 maribavir;ganciclovir
46 A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. Completed NCT00001100 Phase 3 ganciclovir
47 Transfusion-Transmitted Cytomegalovirus Prevention in Neonates Completed NCT00000584 Phase 3 immunoglobulins
48 A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation Completed NCT00227370 Phase 3 valganciclovir
49 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Completed NCT00411645 Phase 3 maribavir
50 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir

Search NIH Clinical Center for Cytomegalovirus Infection

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cidofovir
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Foscarnet
Foscarnet Sodium Hexahydrate
Ganciclovir
Ganciclovir Sodium
Immunoglobulins, Intravenous
valganciclovir
Valganciclovir hydrochloride

Genetic Tests for Cytomegalovirus Infection

Anatomical Context for Cytomegalovirus Infection

MalaCards organs/tissues related to Cytomegalovirus Infection:

40
Kidney, Liver, T Cells, Bone, Heart, Bone Marrow, Lung

Publications for Cytomegalovirus Infection

Articles related to Cytomegalovirus Infection:

(show top 50) (show all 9208)
# Title Authors PMID Year
1
The immunity features and defects against primary cytomegalovirus infection post-splenectomy indicate an immunocompromised status: A PRISMA-compliant meta-analysis. 61 42
31651900 2019
2
British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. 42
31562236 2019
3
Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation. 42
31532960 2019
4
Letermovir as Salvage Therapy for Cytomegalovirus Infection in Transplant Recipients. 61
32000236 2020
5
Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients. 61
31385924 2020
6
Massive ascites and severe pulmonary hypoplasia in a premature infant with meconium peritonitis and congenital cytomegalovirus infection. 61
31198083 2020
7
GATA2 mutation underlies hemophagocytic lymphohistiocytosis in an adult with primary cytomegalovirus infection. 61
31350183 2020
8
Histopathologic Patterns of Colitis in Patients With Impaired Renal Function. 61
31679016 2020
9
Cytomegalovirus Infection Exacerbates Experimental Colitis by Promoting IL-23 Production. 61
31701354 2020
10
Cytomegalovirus Seroprevalence and Birth Prevalence of Congenital CMV Infection in Bosnia and Herzegovina: A Single-Center Experience. 61
31738327 2020
11
Congenital viral infections in England over five decades: a population-based observational study. 61
31708420 2020
12
Do Antivirals Improve Hearing Outcomes in Neonates With Congenital Cytomegalovirus Infection? 61
32010980 2020
13
Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are associated with biliary damage and graft survival in a case-control study. 61
31201006 2020
14
Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. 61
31959979 2020
15
The association of mycophenolate mofetil and human herpes virus infection. 61
30676825 2020
16
Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation. 61
31335770 2020
17
Prenatal findings, neonatal symptoms and neurodevelopmental outcome of congenital cytomegalovirus infection in a university hospital in Montreal, Quebec. 61
32031981 2020
18
The risk of cytomegalovirus infection in daycare workers: a systematic review and meta-analysis. 61
31359142 2020
19
Cytomegalovirus infection and associated hospitalization and costs among individuals undergoing allogeneic hematopoietic stem cell transplant. 61
31490097 2020
20
Cytomegalovirus Infection among Infants in Neonatal Intensive Care Units, California, 2005 to 2016. 61
30895580 2020
21
High prevalence of breastmilk-acquired cytomegalovirus infection in jaundiced infants. 61
31997475 2020
22
Fatal Cytomegalovirus Infection in an Adult with Inherited NOS2 Deficiency. 61
31995689 2020
23
Maternal Cytomegalovirus Infection and Fetal Impairment: Uncertainty Remains. 61
31090901 2020
24
Identification of an Autophagy-Related Signature Predicting Overall Survival for Papillary Thyroid Carcinoma. 61
31975975 2020
25
Etiology of newborn hearing impairment in Guangdong province: 10-year experience with screening, diagnosis, and follow-up. 61
31912317 2020
26
[IgA vasculitis with massive hemorrhage from the jejunum after steroid administration]. 61
31941858 2020
27
Congenital Cytomegalovirus Infection Masquerading as Antenatal Ventriculomegaly With Intraventricular Hemorrhage in a Term Neonate. 61
31839867 2020
28
The MRI spectrum of congenital cytomegalovirus infection. 61
31802515 2020
29
Human cytomegalovirus infection in Iranian glioma patients correlates with aging and tumor aggressiveness. 61
31944314 2020
30
The impact of cytomegalovirus infection on clinical severity and outcomes in kidney transplant recipients with pneumocystis jirovecii pneumonia. 61
31994768 2020
31
Management of BK Viremia is Associated with a Lower Risk of Subsequent Cytomegalovirus Infection in Kidney Transplant Recipients. 61
31994787 2020
32
Evaluation of clinically asymptomatic high risk infants with congenital cytomegalovirus infection. 61
31575999 2020
33
An Unusual Presentation of Cytomegalovirus Infection: Generalized Edema. 61
31013510 2020
34
Productive Cytomegalovirus Infection Is Associated With Impaired Endothelial Function in ST-Elevation Myocardial Infarction. 61
31295440 2020
35
E1021K Homozygous Mutation in PIK3CD Leads to Activated PI3K-Delta Syndrome 1. 61
31953711 2020
36
Should You Follow the Better-Hearing Ear for Congenital Cytomegalovirus Infection and Isolated Sensorineural Hearing Loss? 61
31593522 2020
37
Isolated auditory neuropathy at birth in congenital cytomegalovirus infection. 61
31906974 2020
38
Blood viral load in the diagnostic workup of congenital cytomegalovirus infection. 61
31821950 2020
39
Evaluation of saliva pools method for detection of congenital human cytomegalovirus infection. 61
31678048 2020
40
A Cross-Sectional Study of Caregiver Perceptions of Congenital Cytomegalovirus Infection: Knowledge and Attitudes about Screening. 61
31952844 2020
41
Birth Prevalence of Congenital Cytomegalovirus Infection in HIV-Exposed Uninfected Children in the Era of Combination Antiretroviral Therapy. 61
31668479 2020
42
Performance of the Alethia® CMV assay for the detection of cytomegalovirus using neonatal saliva swabs. 61
31969426 2020
43
Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. 61
31448830 2020
44
Effects of Maribavir on P-Glycoprotein and CYP2D6 in Healthy Volunteers. 61
31385617 2020
45
Prevention of cardiac allograft vasculopathy - A new possible indication for SGLT-2 inhibitors? 61
32006921 2020
46
Prevalence of Infections in Infants Within the First 6 Months of Liver Transplant. 61
32008506 2020
47
Global estimate of phenotypic and genotypic ganciclovir resistance in cytomegalovirus infections among HIV and organ transplant patients; A systematic review and meta-analysis. 61
32004622 2020
48
Postoperative hyperglycemia may negatively impact cytomegalovirus infection in seropositive liver transplant recipients: a retrospective cohort study. 61
31429502 2020
49
Patient characteristics, clinical manifestations, prognosis, and factors associated with gastrointestinal cytomegalovirus infection in immunocompetent patients. 61
32000707 2020
50
Prevention of postnatal cytomegalovirus infection in preterm infants. 61
31865623 2019

Variations for Cytomegalovirus Infection

Expression for Cytomegalovirus Infection

Search GEO for disease gene expression data for Cytomegalovirus Infection.

Pathways for Cytomegalovirus Infection

Pathways related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNF RAG1 NFKB1 MTOR IRF3 IL6
2
Show member pathways
13.97 TNF NFKB1 MTOR IL6 IL1B FAS
3
Show member pathways
13.82 TNF NFKB1 MTOR IL6 IL1B FAS
4
Show member pathways
13.7 TNF SP1 NFKB1 MTOR IL6 IL1B
5
Show member pathways
13.7 TNF SP1 NFKB1 MTOR IL6 IL1B
6
Show member pathways
13.56 NFKB1 MTOR HLA-G HLA-E HLA-B HLA-A
7
Show member pathways
13.56 TNF SP1 NFKB1 MTOR IL6 IL1B
8
Show member pathways
13.45 TNF NFKB1 IL6 IL1B FAS CXCL8
9
Show member pathways
13.22 TNF NFKB1 IRF3 IL6 IL1B FAS
10
Show member pathways
13.12 TNF NFKB1 MTOR IL6 FAS CCL5
11
Show member pathways
13.05 TNF NFKB1 MTOR IRF3 IL6 HLA-G
12 13.01 SP1 NFKB1 MTOR IL6 FAS CXCL8
13
Show member pathways
13 NFKB1 FAS CXCL8 CCL5 CCL3 CCL2
14
Show member pathways
12.97 TNF RAG1 NFKB1 IRF3 IL6 IL1B
15
Show member pathways
12.94 TNF NFKB1 IRF3 IL6 IL1B CXCL8
16
Show member pathways
12.9 TNF NFKB1 IRF3 FAS CASP3
17
Show member pathways
12.89 TNF IL6 IL1B HLA-G HLA-E HLA-B
18
Show member pathways
12.87 TNF NFKB1 MTOR IL6 CREB1
19 12.86 TNF NFKB1 IL1B FAS CASP3
20
Show member pathways
12.84 TNF SP1 NFKB1 IL1B FAS CREB1
21
Show member pathways
12.84 TNF NFKB1 IRF3 IL6 IL1B HLA-G
22
Show member pathways
12.82 NFKB1 MTOR FAS CREB1 CASP3
23
Show member pathways
12.78 TNF NFKB1 MTOR IL6 IL1B FAS
24
Show member pathways
12.77 TNF NFKB1 FAS CREB1 CASP3
25 12.75 TNF RAG1 NFKB1 IRF3 IL1B FAS
26 12.72 TNF NFKB1 MTOR IRF3 IL6 IL1B
27
Show member pathways
12.71 TNF NFKB1 MTOR IL6 IL1B
28
Show member pathways
12.71 IRF3 HLA-G HLA-E HLA-B HLA-A B2M
29
Show member pathways
12.7 TNF NFKB1 IL6 IL1B CCL2
30
Show member pathways
12.7 TNF NFKB1 IL1B FAS CASP3
31
Show member pathways
12.69 TNF HLA-G HLA-E HLA-B HLA-A FAS
32
Show member pathways
12.66 SP1 NFKB1 MTOR IL1B CREB1 CASP3
33
Show member pathways
12.65 SP1 NFKB1 IL6 IL1B CREB1
34
Show member pathways
12.6 HLA-G HLA-E HLA-B HLA-A B2M
35 12.57 TNF NFKB1 MTOR IRF3 IL1B CXCL8
36
Show member pathways
12.55 TNF SP1 NFKB1 IL6 IL1B CXCL8
37
Show member pathways
12.52 TNF IL6 CXCL8 CCL5 CCL3 CCL2
38
Show member pathways
12.52 TNF NFKB1 IL6 IL1B CCL5 CCL2
39
Show member pathways
12.51 TNF NFKB1 IRF3 IL6 IL1B CXCL8
40 12.5 NFKB1 IRF3 HLA-G HLA-E HLA-B HLA-A
41
Show member pathways
12.49 SP1 NFKB1 CREB1 CCL2
42 12.49 TNF NFKB1 IL6 IL1B FAS CXCL8
43
Show member pathways
12.46 TNF IRF3 IL6 IL1B HLA-G HLA-E
44 12.45 TNF NFKB1 IL6 HLA-G HLA-E HLA-B
45
Show member pathways
12.43 SP1 NFKB1 MTOR CREB1
46 12.43 TNF NFKB1 IRF3 IL6 IL1B CXCL8
47
Show member pathways
12.42 TNF NFKB1 IRF3 IL6 CXCL8
48 12.42 TNF NFKB1 IL6 IL1B CREB1 CASP3
49 12.4 TNF MTOR FAS CASP3
50
Show member pathways
12.4 TNF SP1 NFKB1 IL6 IL1B CXCL8

GO Terms for Cytomegalovirus Infection

Cellular components related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.18 TNF NFKB1 IL6 IL1B HLA-G HLA-E
2 extracellular space GO:0005615 10.11 TNF IL6 IL1B HLA-G HLA-E HLA-B
3 cell surface GO:0009986 9.93 TNF HLA-E HLA-B HLA-A FAS B2M
4 early endosome membrane GO:0031901 9.83 HLA-G HLA-E HLA-B HLA-A B2M
5 recycling endosome membrane GO:0055038 9.65 HLA-G HLA-E HLA-B HLA-A B2M
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.62 HLA-G HLA-E HLA-B HLA-A
7 phagocytic vesicle membrane GO:0030670 9.55 HLA-G HLA-E HLA-B HLA-A B2M
8 death-inducing signaling complex GO:0031264 9.48 FAS CASP3
9 ER to Golgi transport vesicle membrane GO:0012507 9.35 HLA-G HLA-E HLA-B HLA-A B2M
10 MHC class I protein complex GO:0042612 9.02 HLA-G HLA-E HLA-B HLA-A B2M

Biological processes related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 NFKB1 IL6 IL1B FAS CXCL8 CREB1
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.27 TNF SP1 NFKB1 IRF3 IL6 IL1B
3 immune system process GO:0002376 10.18 IRF3 HLA-G HLA-E HLA-B HLA-A B2M
4 positive regulation of transcription, DNA-templated GO:0045893 10.18 TNF SP1 NFKB1 IRF3 IL6 IL1B
5 positive regulation of gene expression GO:0010628 10.12 TNF SP1 MTOR IL6 IL1B CCL3
6 positive regulation of apoptotic process GO:0043065 10.1 TNF IL6 FAS CREB1 CASP3
7 inflammatory response GO:0006954 10.1 TNF NFKB1 IL6 IL1B CXCL8 CCL5
8 MAPK cascade GO:0000165 10.05 TNF IL1B CCL5 CCL3 CCL2
9 regulation of immune response GO:0050776 10.04 HLA-G HLA-E HLA-B HLA-A B2M
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.03 TNF CCL5 CCL3 CCL2
11 cytokine-mediated signaling pathway GO:0019221 10.03 TNF IL6 IL1B CXCL8 CCL5 CCL3
12 positive regulation of protein phosphorylation GO:0001934 10.01 TNF MTOR IL1B FAS
13 cellular response to tumor necrosis factor GO:0071356 10 NFKB1 CXCL8 CCL5 CCL3 CCL2
14 cellular response to lipopolysaccharide GO:0071222 10 TNF NFKB1 IRF3 IL6 IL1B CXCL8
15 chemotaxis GO:0006935 9.99 CXCL8 CCL5 CCL3 CCL2
16 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF NFKB1 IL6 IL1B
17 neutrophil chemotaxis GO:0030593 9.96 IL1B CXCL8 CCL5 CCL3 CCL2
18 cellular response to interleukin-1 GO:0071347 9.95 NFKB1 CXCL8 CCL5 CCL3 CCL2
19 chemokine-mediated signaling pathway GO:0070098 9.93 CXCL8 CCL5 CCL3 CCL2
20 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.93 HLA-G HLA-E HLA-B HLA-A B2M
21 cellular response to mechanical stimulus GO:0071260 9.92 NFKB1 IL1B FAS
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.92 TNF MTOR IL6 CCL5
23 type I interferon signaling pathway GO:0060337 9.92 IRF3 HLA-G HLA-E HLA-B HLA-A
24 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 TNF IL6 CCL5
25 regulation of insulin secretion GO:0050796 9.91 TNF IL1B CCL5
26 response to glucocorticoid GO:0051384 9.9 TNF IL6 CASP3
27 apoptotic signaling pathway GO:0097190 9.9 TNF FAS CASP3
28 positive regulation of T cell proliferation GO:0042102 9.9 IL6 IL1B CCL5
29 positive regulation of interleukin-6 production GO:0032755 9.9 TNF IL6 IL1B
30 positive regulation of neuron apoptotic process GO:0043525 9.89 TNF CCL3 CASP3
31 humoral immune response GO:0006959 9.89 TNF IL6 CCL2
32 monocyte chemotaxis GO:0002548 9.88 IL6 CCL5 CCL3 CCL2
33 protein kinase B signaling GO:0043491 9.88 TNF IL1B CCL5 CCL3 CCL2
34 visual learning GO:0008542 9.87 RAG1 MTOR CREB1
35 negative regulation of neurogenesis GO:0050768 9.87 TNF IL6 IL1B B2M
36 positive regulation of epithelial to mesenchymal transition GO:0010718 9.86 MTOR IL6 IL1B
37 positive regulation of nitric oxide biosynthetic process GO:0045429 9.86 TNF MTOR IL1B
38 antigen processing and presentation GO:0019882 9.85 HLA-E HLA-B HLA-A
39 lymphocyte chemotaxis GO:0048247 9.85 CCL5 CCL3 CCL2
40 interferon-gamma-mediated signaling pathway GO:0060333 9.85 IRF3 HLA-G HLA-E HLA-B HLA-A B2M
41 cellular response to fibroblast growth factor stimulus GO:0044344 9.84 CXCL8 CCL5 CCL2
42 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 CCL5
43 positive regulation of T cell mediated cytotoxicity GO:0001916 9.83 HLA-G HLA-E HLA-B
44 eosinophil chemotaxis GO:0048245 9.81 CCL5 CCL3 CCL2
45 positive regulation of glial cell proliferation GO:0060252 9.81 TNF MTOR IL6 IL1B
46 macrophage chemotaxis GO:0048246 9.8 CCL5 CCL3 CCL2
47 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.8 HLA-G HLA-E HLA-B HLA-A B2M
48 positive regulation of neuroinflammatory response GO:0150078 9.79 TNF IL6 IL1B
49 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.77 HLA-G HLA-E HLA-B
50 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.77 HLA-G HLA-E HLA-B

Molecular functions related to Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.3 TNF SP1 RAG1 NFKB1 MTOR IRF3
2 protein homodimerization activity GO:0042803 9.98 SP1 RAG1 NFKB1 IRF3 HLA-G CCL5
3 transcription regulatory region DNA binding GO:0044212 9.77 TNF SP1 NFKB1 IRF3 CREB1
4 CCR chemokine receptor binding GO:0048020 9.58 CCL5 CCL3 CCL2
5 chemokine activity GO:0008009 9.56 CXCL8 CCL5 CCL3 CCL2
6 beta-2-microglobulin binding GO:0030881 9.51 HLA-E HLA-A
7 cytokine activity GO:0005125 9.5 TNF IL6 IL1B CXCL8 CCL5 CCL3
8 phospholipase activator activity GO:0016004 9.49 CCL5 CCL3
9 CCR5 chemokine receptor binding GO:0031730 9.48 CCL5 CCL3
10 CCR1 chemokine receptor binding GO:0031726 9.46 CCL5 CCL3
11 peptide antigen binding GO:0042605 9.46 HLA-G HLA-E HLA-B HLA-A
12 identical protein binding GO:0042802 9.36 TNF RAG1 NFKB1 MTOR IRF3 HLA-G

Sources for Cytomegalovirus Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....